| Market Cap | 6.90M | P/E | - | EPS this Y | 54.60% | Ern Qtrly Grth | - |
| Income | -11.38M | Forward P/E | -0.74 | EPS next Y | 10.50% | 50D Avg Chg | -4.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -76.00% |
| Dividend | N/A | Price/Book | 0.17 | EPS next 5Y | - | 52W High Chg | -97.00% |
| Recommedations | 3.00 | Quick Ratio | 0.21 | Shares Outstanding | 1.61M | 52W Low Chg | 12.00% |
| Insider Own | 1.48% | ROA | -44.76% | Shares Float | 532.96K | Beta | 0.58 |
| Inst Own | 3.25% | ROE | -150.80% | Shares Shorted/Prior | 35.91K/113.12K | Price | 1.34 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 335,922 | Target Price | 7.00 |
| Oper. Margin | - | Earnings Date | Nov 7 | Volume | 36,077 | Change | -4.29% |
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
| HC Wainwright & Co. | Neutral | Jan 3, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Fraser Craig | President and CEO President and CEO | Sep 27 | Buy | 1.0199 | 2,500 | 2,550 | 57,877 | 09/28/23 |
| Fraser Craig | President and CEO President and CEO | Sep 26 | Buy | 0.90 | 2,500 | 2,250 | 55,377 | 09/27/23 |
| Fraser Craig | President and CEO President and CEO | Apr 26 | Buy | 1.77 | 1,497 | 2,650 | 7,010 | 04/27/23 |
| Fraser Craig | President and CEO President and CEO | Apr 25 | Buy | 1.89 | 1,315 | 2,485 | 5,513 | 04/26/23 |
| Hamill John P. | SVP & CFO SVP & CFO | Jul 26 | Buy | 0.3666 | 3,000 | 1,100 | 72,800 | 07/26/22 |
| Fraser Craig | President and CEO President and CEO | Jul 26 | Buy | 0.374 | 2,500 | 935 | 224,058 | 07/26/22 |
| Fraser Craig | President and CEO President and CEO | Jun 29 | Buy | 0.4154 | 7,000 | 2,908 | 217,058 | 06/30/22 |
| Fraser Craig | President and CEO President and CEO | Mar 16 | Buy | 0.9799 | 2,000 | 1,960 | 210,058 | 03/17/22 |
| Simonson Steven | SVP, Chief Medical O.. SVP, Chief Medical Officer | Mar 15 | Buy | 0.9998 | 5,000 | 4,999 | 83,602 | 03/15/22 |
| Fraser Craig | President and CEO President and CEO | Mar 15 | Buy | 0.9801 | 3,000 | 2,940 | 208,058 | 03/15/22 |
| Center Laboratories, Inc. | 10% Owner 10% Owner | May 20 | Buy | 4.43 | 1,294,260 | 5,733,572 | 1,239,088 | 01/10/22 |
| Bioengine Capital Inc. | 10% Owner 10% Owner | May 20 | Buy | 7.25 | 55,172 | 399,997 | 1,239,088 | 01/10/22 |
| Bioengine Capital Inc. | 10% Owner 10% Owner | May 20 | Sell | 1.6 | 1,239,088 | 1,982,541 | 01/10/22 |